Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: CLAIM_LEVEL_HUMAN_REVIEW_REQUIRED
Scutellaria lateriflora has limited identity-matched human evidence. A recent randomized crossover sleep trial and an earlier mood trial justify further study, but they do not validate unspecified 'skullcap' species or low-dose combination products.

Origin & History

Skullcap (Scutellaria lateriflora) is a perennial herb native to North American wetlands and meadows, ranging from Canada to Florida. It is sourced from the aerial parts (leaves, stems, and flowers) of the plant, with extraction typically involving hot water or solvents to yield dried leaf extracts containing approximately 50 mg/g total flavonoids.
Research Narrative (Provisional)
A 2025 randomized double-blind crossover trial evaluated Scutellaria lateriflora at 400 mg/day for sleep outcomes (PMID 40362800). An earlier randomized study examined mood effects (PMID 23878109). These results apply to the named species and study preparations, not every product labeled skullcap.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Skullcap (Scutellaria lateriflora) is used primarily as a medicinal herb rather than a nutritional food source, so macronutrient content (protein, fat, carbohydrate) is negligible at typical dosing (1–2 g dried herb or 2–4 mL tincture). Its therapeutic value derives from its bioactive compound profile: Key Flavonoids (primary active constituents): • Baicalin: ~2–6% of dried aerial parts (major glycoside; converted to baicalein by gut microbiota, improving bioavailability) • Baicalein (aglycone): ~0.5–2% of dried herb; higher bioavailability than baicalin; binds GABA-A receptors at the benzodiazepine site • Scutellarein: ~0.3–1.5%; methoxylated flavone with anti-inflammatory and neuroprotective activity • Wogonin: ~0.1–0.8%; anxiolytic flavone that also modulates GABA-A receptors • Wogonoside (wogonin-7-glucuronide): ~0.2–1.0% • Lateriflorin: trace amounts; iridoid compound relatively unique to S. lateriflora • Oroxylin A: trace to ~0.3%; cognitive-enhancing flavone • Chrysin: trace amounts; weak GABA-A modulator Other Bioactive Compounds: • Iridoids (catalpol, lateriflorin): trace to low concentrations; contribute to bitter tonic properties • Phenolic acids (caffeic acid, ferulic acid): ~0.1–0.5%; antioxidant activity • Volatile oils (limonene, terpineol, others): trace; contribute to aromatic profile • Tannins: ~2–4% of dried herb; condensed and hydrolyzable types • Lignins and polysaccharides: present in small amounts Minerals (per gram of dried herb, approximate): • Calcium: ~5–12 mg/g • Magnesium: ~2–4 mg/g • Potassium: ~10–20 mg/g • Iron: ~0.05–0.2 mg/g • Zinc: trace • Manganese: trace Vitamins: • Minimal vitamin content at typical medicinal doses; trace amounts of vitamin C and B-complex vitamins typical of leafy aerial plant parts Fiber: • Dried herb contains ~15–25% crude fiber, but given small doses consumed, dietary fiber contribution is negligible Bioavailability Notes: • Baicalin (glycoside) has relatively low oral bioavailability (~2–5%) due to poor intestinal absorption; however, gut microbiota hydrolyze it to baicalein, which is absorbed more readily (bioavailability ~10–20%) • Wogonin and baicalein are lipophilic aglycones with moderate oral bioavailability; absorption is enhanced when taken with small amounts of dietary fat • Tincture (hydroethanolic extract) preparations generally improve extraction and bioavailability of flavonoids compared to simple aqueous infusions • Glucuronidation in the liver is a major metabolic pathway for all key flavonoids, producing conjugates that undergo enterohepatic recirculation, prolonging activity • Concurrent intake with grapefruit juice or other CYP3A4 inhibitors may theoretically increase flavonoid plasma levels, though this has not been clinically studied for skullcap specifically
Reported Mechanism (Provisional)
Skullcap's primary bioactive compounds baicalin, baicalein, and wogonin bind to benzodiazepine receptor sites, enhancing GABAergic neurotransmission. These flavonoids also inhibit 5-lipoxygenase and cyclooxygenase pathways, reducing inflammatory mediator production. The compounds cross the blood-brain barrier and modulate calcium channels in neural tissue.
Clinical Narrative (Provisional)
Evidence grade: limited. Species ambiguity is a major safety and evidence-transfer problem in skullcap products.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







